Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 3, 2012, Pages 355-360

  Escudero Vilaplana, Vicente ^a   Ramírez Herraiz, Esther ^b   Trovato López, Nicolás ^a   Alañón Plaza, Estefanía ^b   Bellini, María José ^a   Herranz Alonso, Ana ^a   Bellón Cano, José María ^a   Morell Baladrón, Alberto ^b   Sanjurjo Sáez, María ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; COST CONTROL; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE 28; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; EARLY INTERVENTION; EUROPEAN LEAGUE AGAINST RHEUMATISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; THERAPEUTIC SPACING;

EID: 84863480555     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/J33W30     Document Type: Article

References (20)

1. Del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum, 2001;44(12):2737-2745.
2. Abásolo L, Júdez E, Descalzo MA, González-Alvaro I, Jover JA, Carmona L, on behalf of the EMECAR Study Group. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum, 2008;37(6):388-397.
3. Carmona L, Villaverde V, Hernandez-Garcia C, Ballina J, Gabriel R, Laffon A. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology. 2002;41(1):88-95.
4. Blumberg SN, Fox DA. Rheumatoid arthritis: guidelines for emerging therapies. Am J Manag Care, 2001;7(6):617-626.
5. Eberhardt KB, Fex E. Functional impairment and disability in early rheumatoid arthritis--development over 5 years. J Rheumatol, 1995;22(6):1037-1042.
6. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology, 2000;39(2):122-132.
7. Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol, 2006;20(5):849-863.
8. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis, 2010;69(4):631-637.
9. Ma MH, Kingsley GH, Scott DL. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology, 2010;49(1):91-98.
10. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum, 2006;54(1):26-37.
11. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum, 2008;58(2):S126-S135.
12. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum, 1998;41(10):1845-1850.
13. Carmona L, Ballina J, Gabriel R, Laffon A, on behalf of the EPISER Study Group. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis, 2001;60:1040-1045.
14. Ruiz-Montesinos MD, Hernández-Cruz B, Ariza-Ariza R, Carmona L, Ballina J, Navarro-Saravia F, on behalf of the Grupo de Estudio de Costes y Calidad de Vida en Artritis Reumatoide de la Sociedad Española de Reumatología. Análisis de costes en una cohorte de enfermos con artritis reumatoide atendidos en área especializada de reumatología en España. Reumatol Clin, 2005;1:193-199.
15. Rubio-Terrés C, Ordovás Baines JP, Pla Poblador R, Martínez Nieto C, Sánchez Garre MJ, Rosado Souvirón MA, et al. Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study). Farm Hosp, 2007;31(2):78-92.
16. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum, 2005;34(5):19-22.
17. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum, 2006;54(3):711-715.
18. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis, 2007;66(7):921-926.
19. Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol, 2006;33(1):31-36.
20. Moots RJ, Haraoui B, Matucci-Cerinic M, van Riel PL, Kekow J, Schaeverbeke T, et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol, 2011;29(1):26-34.